L infettivologia del 3 millennio: AIDS ed altro
|
|
|
- Charity Porter
- 8 years ago
- Views:
Transcription
1 L infettivologia del 3 millennio: AIDS ed altro VI Convegno Nazionale maggio 2014 Centro Congressi Hotel Ariston Paestum (SA)
2 La deintensificazione terapeutica in HIV: Razionale e vantaggi della mono e della dual-therapy Paestum (Sa) maggio 2014 Diego Ripamonti, Malattie Infettive, Bergamo
3 HIV treament paradigm Deeks SG et al. Lancet, November 2013
4 The burden of HIV disease Failure clinical aging drug toxicity non-aids diseases persistent IA HIV disease management Success Deeks S et al. Lancet 2013; 382:
5 The burden of HIV disease Failure clinical aging HIV disease management drug toxicity non-aids diseases persistent IA Success Deeks S et al. Lancet 2013; 382:
6 lipodistrofia SNC mtdna HAART Toxicity rene cardiovascolare osso
7 Changes in Fat Mitochondrial DNA and Function by type of NRTIs (A5224s study): 39 paired samples P =.03 P <.001 In addition, in subjects treated with TDF/FTC (but not ABC/3TC), there was evidence of mitochondrial respiratory chain dysfunction. Median change in mtdna over 2 years: -340 and -400 copies (p=0.57) McComsey GA, et al. J Infect Dis 2013;207:604 11
8 ACTG A5224s Study, 269 pts, DXA scans Mean percentage change in lumbar spine BMD by ITT analysis. Regimi con minore tossicità McComsey G A et al. J Infect Dis. 2011;203:
9 Sostenibilità economica Farmaci Farmaci Popolazione infetta regimi meno costosi Popolazione infetta Raffi F, Reynes J. JAC 2014;69:
10 Minore tossicità + Minor costo Strategie alternative Personalised HIV medicine 4 drugs HAART dual therapy monotherapy
11 Is HAART de-intensification possible? PI monotherapy in naive: Monark study Dual therapy in heavily treated patients Functional monotherapy in experienced pts % < 50 copie MONARK 75 Viremic and aviremic pts are different settings New agents and new combinations 0 LOP/r Mono HAART 83 versus 53 pts v.l. < 10 5 ; CD4 > 100 cells 48 weeks, < 50 copies Meynard JL et al JAC 2010
12 HIV RNA dual therapy Boosted IP - high genetic barrier - low risk of resistance at failure monotherapy time
13 DUAL THERAPY Any combination? 1. Genetic barrier of the regimen 2. Antiviral potency of single agents 3. Drug-to-drug interactions 4. Toxicity profile 5. PK simmetry 6. Forgiveness of the regimen 7. Penetration into compartments 8. Convenience
14 DUAL regimens LOP/r DRV/r PROGRESS GARDEL NEAT MODERN GUSTA 206 pts naive Abbott 416 pts naive international 800 pts naive European 804 pts naive ViiV 330 pts switch Italy LOP/r +TDF/FTC LOP/r + RAL LOP/r +2NRTIs LOP + 3TC bid DRV/r + TDF/FTC DRV/r + RAL DRV/r + TDF/FTC DRV/r + MRV od 150mg DRV/r + TDF/FTC DRV/r + MRV od 300mg 96 weeks 48 weeks 96 weeks 48 weeks 48 weeks completed completed completed stop ongoing
15 Phase III, randomized, international, controlled, open-label study (Argentina, Chile, Mexico, Peru, Spain, US.) DT: LPV/r 400/100mg BID + 3TC 150 mg BID (n=217) TT: LPV/r 400/100mg BID + (3TC or FTC) + (NRTI) (n=209) Viral load <50 copies/ml at week 48 (ITTe) Viral load <50 copies/ml at week 48 (ITTe), baseline VL > copies/ml 100% 90% 80% DT TT 87.2% 70% 77.9% 60% 50% 40% Keep 30% an open mind 20% 10% 0% BSL W4 W8 W12 W24 W36 W48 Primary endpoint : % of patients with HIV-1 RNA< 50 copies/ml in an ITT-exposed analysis at 48 weeks (FDA-snapshot algorithm).* HIV RNA >10 5 c/ml = 43% CD4 < 200 c/mmc = 19% NRTIs (%) ABC/3TC: 9.5 TDF/FTC: 36 ZDV/3TC: 54 M184V mutations: 2 in dual arm Cahn P et al. EACS 2013
16 CROI 2014 NRTI-based regimens are robust! CD4 gain at wk 96 = 267 vs 266 c/mmc
17 CROI 2014
18 PROGRESS: proportion of subjects responding at week 96 (FDA-TLOVR) CD4: 281 vs 286 cells PROGRESS 96 Week Results April 9,
19 MODERN study Do not assume potency! drug-to-drug interactions?
20 Which benefit for NRTI-sparing regimens?
21 PROGRESS study In 210 participants, DEXA scans at T0 and T48 wk Martin A, et al AIDS 2013;27:
22 if we just stop TDF?
23 Total BMD % ATLAS study ATV/r +3TC 300mg *40 pts, 97.5% discontinued TDF. Femoral neck Lumbar spine Di Giambenedetto et al. JAC 2013;68:
24 ATLAS study ATV/r +3TC 300mg *40 pts, 97.5% discontinued TDF. TC +17 mg/dl HDL-C +6 mg/dl egfr +7.3 ml/min Di Giambenedetto et al. JAC 2013;68:
25 and PI-sparing dual regimen?
26 + NVP (Montrucchio et al. ICAAR 2013) RAL + MRV (Katlama C et al. JAC 2014 Nozza S et al. JAC 2014) + ETR (Calin R et al. IAS 2013 Monteiro P et al. JAC 2014)
27 MRV300mg bid + RAL 400mg bid Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study Switch study in 44 aviremic (median time: 5.2 years), nadir CD4: > 100 [median 210 ( )] cells, R5 tropic virus on HIV-DNA, with lypodistrophy. VF in 5/44 patients (11.4%, CI: ) < 24 weeks Resistance to RAL (F121Y, Y143C, N155H) in 3/5 patients and switch from R5 to X4 tropic virus in 2/5 patients. Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection Katlama C et al. JAC 2014;69:1648 Una coppia non è necessariamente solida!!! Switch study in 26 aviremic, but extensively experienced pts R5 tropic virus on HIV-DNA. VF in 9/26 (35%) < 24 weeks. Resistance to RAL ( Y143C, N155H) in 5/9 patients Nozza S. et al. JAC 2014;69:1436
28 ETR 200mg BID + RAL 400mg BID - Observational, single centre. - Switch study in 91 aviremic, median F-up: 11.5 months ( ) - Follow up: 65 pts (month 6), 48 pts (month 12). - PP analysis: 98.2% (6 mos) and 92.3 % (12 mos) had HIV RNA < 50 copies VF in 3 patients Pts Previous NNRTI Previous NNRTI mutation Genotype at failure 1 yes V179I - <6 2 yes 72I yes K103N, Y181C, 225H, 181C, 155H 6-12 Time since switch (months) Calin R et al. IAS 2013; P WEPE516
29 PI MONOTHERAPY (maximal de-intensification)
30 Efficacy and durability for boosted PI monotherapy KALESOLO study 186 pts Meynard JL et al. JAC 2010 LOP/r 400/100 mg bid + 2NRTI LOP/r 400/100 mg bid 96 weeks OK04 study 198 pts Pulido F et al. ICAAC 2009 LOP/r 400/100 mg bid + 2NRTI LOP/r 400/100 mg bid 96 weeks LOP/r 400/100 mg bid 144 weeks MONET study 256 pts Arribas J et al. 6 th IAS 2011 DRV/r 800/100 mg od + 2NRTI DRV/r 800/100 mg od 144 weeks MONOI study 225 pts Valantin M et al. JAC 2012 DRV/r 600/100 mg bid + 2NRTI DRV/r 600/100 mg bid DRV/r 800/100 mg od + 2NRTI DRV/r 800/100 mg od 48 weeks 96 weeks
31 PI/r monotherapy trials: virological efficacy OK04 study (96 wks) 198 patients LOP/r bid vs HAART HIV RNA < 50 copies/ml Analysis: ITT, M=F, R=F p=ns Arribas JR et al. JAIDS MONOI (96 wks) 225 patients DRV/r vs HAART HIV RNA < 50 copies/ml Analysis: ITT, withdrew consent=f, M=F 88 MONO p=ns 84 HAART MONET (144 wks) 256 patients DRV/r od vs HAART HIV RNA < 50 copies/ml Analysis: PP, M=F 74,5 78,2 Lambert-Niclot S et al. PLoS One Arribas JR et al. HIV Med % (95%CI: ) MONO HAART
32 Efficacy and durability for boosted PI monotherapy MODAt study 342 pts Castagna A. et al. EACS 2013 ATV/r 300/100 mg + 2NRTIs STOP ATV/r 300/100 mg 48 weeks PIVOT study 582 pts Paton A. et al. CROI 2014 PI/r + 2NRTIs PI/r Median 44 months
33 48 weeks virological efficacy (%) MODAt 48 weeks virological efficacy No mutations in pts failing ATV/r ATV/r ATV/r+ 2NRTIs % 85% 92% 85% ITT re-intensification=failure ITT re-intensification=success Difference (95% CI): -12.1% (-27.8% to 3.6%) 7.5% (-4.7% to 19.8%) BL CD4+ (cells/ µl) 599 ( ) 570 ( ) 48 weeks CD4+ change (cells/µl) 50 (-21/+131) 33 (-34/+136) Castagna A. et al, EACS 2013
34 48 weeks virological efficacy (%) MODAt Virological efficacy according to HCV coinfection on June 2013 DSMB recommended to stop enrollment and to follow until 96 weeks patients on study ATV/r 100 P=0.050 P=0.064 ATV/r + 2NRTIs % 83% 45% 90% 0 Without HCV co-infection With HCV co-infection Castagna A. et al, EACS 2013
35 PIVOT Trial (44 UK HIV centres) PI/r + 2NRTIs 291 pts PI/r 296 pts Difference (95%CI) P value VL > 50 copies n (%) 8 (3.2) 95 (35) 31.8 (24.6 to 39) <0.001 Loss of future options (by 36 mos) Loss of future options n (%) (by the end of trial) 2 (0.7) 6 (2.1) 1.4 (-0.4 to 3.4) (1.8%) 6 (2.1%) 0.2% (-2.5 to 2.6) 0.85 CD4 change (SE) +91 (9) +108 (9) +17 (-10 to +43) 0.21 Serious AE n(%) 8 (2.8) 15 (5.1) Grade 3-4 AEs 159 (55%) 137 (46%) Neuro-cognitive Function mean change Median follow up: 44 months -8.4% (-16.4 to 0.3) ( to +0.09) 0.86 Paton N et al. CROI 2014; Abs 550LB
36 MONET Week 144 analysis: HIV RNA <5 versus time on DRV/r monotherapy (observed data analysis) >400 copies/ml copies/ml 5-50 copies/ml <5 copies/ml % patients DRV/r + 2 NRTIs DRV/r 100% 100% 90% 90% 80% 80% 70% 70% 60% 60% 50% 50% 40% 40% 30% 30% 20% 20% 10% 10% 0% SCR % SCR Time - Weeks Table EFF 1 08/03/11
37 MONET study: HIV-1 DNA change by treatment group from baseline to 144 wks HIV DNA copies/ml p= ns p= ns 94 paired samples N. pts 71 / / 44 Mean change from baseline (Log copies/10 6 PBMC) / p= ns Geretti AM et al. HIV Clin Trials 2013;14:45-50
38 Risks of monotherapy compared to HAART Study (N of pts) Follow-up OK04 1 (100 vs 98) 96 weeks MONOI 2 (112 vs 113) 96 weeks MONET 3 (127 vs 126) 144 weeks Primary PI mutations Resistance mutations at failure secondary PI mutations 2 vs vs 3.5 (in 15 patients) mutations in gag gene Immune recovery mean CD4 count increase salvage Efficacy of reinduction No difference +71 vs % (10/12) 1 vs 0 1/9 patients No difference +70 vs % (5/5) 1 vs 1 No difference Not done +95 vs % (6/7) non statisticamente significativo; mutazione V11I, già presente 7 anni prima; For all comparisons: mono vs triple arm 1. Arribas J. JAIDS 2009; 2. Valantin M. JAC 2012; 3. Arribas J. HIV Med 2012
39 Which patients can qualify for PI mono? 1. Switch strategy in virologically suppressed patients (PI- or NNRTI-based Rx) 2. Nadir CD4+ count > 100 c/mm³ [1-3] or HIV-1 RNA <10 5 c/ml [4] 3. No need of NRTIs (HIV-related encephalopathy. HBV coinfection ) 4. Patients with optimal adherence 5. Long (?) history for suppression 6. No history of PI failure 7. Patients able to tolerate low-dose RTV 8. HCV coinfection (?) A large proportion of selected patients can be treated with PI mono (~70-75% after 3 years are still suppressed in RCTs) 1. Pulido F et al. Antivir Ther. 2009;14: Campo R et al. CROI Abstract Gutmann C et al. AIDS. AIDS. 2010;24: Katlama C et al. AIDS ;24:
40 PI monotherapy and the brain - PROTEA and PIVOT trials ongoing
41 NCI n patients treated with PI monotherapy compared to triple regimens Observational, cross sectional, DRV/r or LOPV/r monotherapy vs triple, 191 pts P= % 25.0% 21.4% 96 pts 40 pts 55 pts Pérez-Valero I, et al PLoS ONE (7): e69493
42 Summary NRTI-based regimens: Restano lo standard di riferimento nei pazienti naive. NRTI-sparing regimens (Dual): Opzione possibile in pazienti naive (NEAT 01, Gardel). Solitamente regimi PI-based. Attenzione alle dosi ed alla combinazioni. Minor tossicità rispetto ai TDF-based regimens (BMD, renal). Di solito regimi più costosi della NRTI-based HAART. Monoterapia Solo con PI boosted Solo in strategia di switch in pazienti selezionati Meno costosi di altri regimi
43 GRAZIE
44 Deintensification strategies DUAL PI MONO Treatment Paradigm Combination regimen single drug Settings viremic, failing or switch switch Options NRTI- sparing NRTI- sparing RTV- and PI-sparing? Drug exposure higher minimal Risks higher risk of resistance mutations at failure NO marginal risk Control in different compartments potentially more potentially less Costs ± expensive cheaper Randomized Clinical Trials Progress, Earnest NEAT 001, Gardel 4 RCTs, up to 144 weeks
45 How PI monotherapy compares to HAART? Can a «single drug» regimen suppress plasma HIV RNA? Which price at virological failure? Which risks for intermittent viremia Durability? CD4 count evolution? How many patients can benefit? How to select patients? Which effect on HIV DNA reduction and evolution? Can HIV be controlled in compartments other than plasma?
46 Low level viremia in monotherapy arms MONET (144 weeks) Observed data analysis 100 MONOI (48 weeks) Observed data analysis < 1 copies/ml other HIV RNA pts 108 pts Data on file, Janssen 0 MONO HAART 101 pts 96 pts Lambert-Niclot S et al. JID 2011
47 Risk factors for HIV RNA > 50 copies/ml monotherapy arms in randomized trials Study Multivariate analysis Risk factors OR, 95%CI P value OK + OK pts, 144 weeks - > 2 missed visits - Haemogobin (per 1 g/dl increase) - Nadir CD4 (>100 vs > 100 cells) 6.30 ( ) 0.68 ( ) 4.1 ( ) <0.002 <0.013 <0.02 MONOI pts, 96 weeks - Adherence (<100% or 100%) - HAART duration (5 ys decrease) - HIV DNA at D0 (1 Log increase) 3.84 ( ) 2.93 ( ) 2.66 ( ) <0.02 <0.006 <0.04 MONET pts, 144 weeks - HCV coinfection 4.5 ( ) < Pulido F et al. Antiv Ther 2009;14: Lambert-Niclot S et al. JID 2011;204: Rieger et al. WAC July 2010, Vienna [abstr TBLBB209]
48 BACK UP
49 Calcagno A et al
50 Obemeier et al. EACS 2013, Brussels. Poster PE10/15
51 SALT: 24 weeks interim analysis No virological failures
52
53 MONET 96-week: low-level viremia with DRV/r monotherapy >1000 copies/ml copies/ml copies/ml <50 copies/ml DRV/r + 2 NRTIs DRV/r 100% 100% 80% 80% 60% 60% 40% 40% 20% 20% 0% 0% Clumeck N, et al. HIV10, Abstract O-19
54 MONET: DRV/r MT does not increase IL-6 or hs-crp levels Levels of the inflammatory markers, interleukin-6 (IL-6) and C-reactive protein (CRP), are elevated in HIV-infection. High levels of IL-6 (>3 pg/ml) and CRP (>5 mg/l) have been associated with more rapid progression to AIDS and death 1 Marker DRV/r + 2 NRTIs DRV/r monotherapy IL-6 >3 pg/ml 20/65 (31%) 15/64 (23%) hs-crp > 5 mg/l 8/80 (10%) 9/75 (12%) p=n.s. for both comparisons, chi-square test There was no difference between the treatment arms in IL-6 or hs-crp levels at the Week 144 visit 1. Rodger A, et al. JID 2009, 200: Arribas JR, et al. EACS, Belgrade, Serbia, October Abstract PS 10/2.
55 Half-life of antiretrovirals 1. Moore KH, et al. AIDS 1999;13: Kewn S, et al. Antimicrob Agents Chemother 2002;46: Hawkins T, et al. 5th IWCPHT, Abstract Product SmPCs. 5. Tibotec, data on file. 1. Moore KH, et al. AIDS 1999;13: Kewn S, et al. Antimicrob Agents Chemother 2002;46: Hawkins T, et al. 5th IWCPHT, Abstract Product SmPCs. 5. Tibotec, data on file.
56 Neurocognitive impairment and virological efficacy in monotherapy compared to HAART Observational, cross sectional, LOPV/r monotherapy vs triple (> 96wks), 34 pts 17 pts 17 pts CSF HIV RNA: (< 1 copy/ml) 82.4 versus 94.1% p= 0.6 Santos JR, et al PLoS ONE 2013;8:e70201
57 LPV/r monotherapy Gutman Ch et al. CROI 2009; Abs 189
58 Gutman Ch et al. CROI 2009; Abs 189
59 ACTG A5224s Study, 269 pts, DXA scans Mean percentage change in hip BMD by ITT analysis. McComsey G A et al. J Infect Dis. 2011;203:
60 Lopinavir Monotherapy and CSF Replication in IMANI significance of these data? Few data comparing CSF VL on triple therapy vs monotherapy Yeh R, et al. CROI Abstract 381.
61 Single arm, phase IV study 39 naive pts CD4 > 50 cells HIV RNA : > 5000 c/ml Among 3 subjects with available genotypes: Primary PI resistance = 0 mutations M184V mutation = 3/3. Andrade R et al. IAS 2011, Rome
62 48 weeks virological efficacy (%) Efficacy and durability for boosted PI monotherapy MODAt study 342 pts on ATV/r ATV/r 300/100 mg + 2NRTI ATV/r 300/100 mg 96 weeks ATV/r pts 52 pts 73% 85% 92% 85% ITT re-intensification=failure ITT re-intensification=success ATV/r+ 2NRTIs Difference (95% CI): -12.1% (-27.8% to 3.6%) 7.5% (-4.7% to 19.8%) No mutations in pts failing ATV/r Castagna A et al. EACS 2013
63 Body fat distribution in patients on DRV/r monotherapy vs DRV/r+ 2NRTIs: the MONOI-ANRS136 Substudy. Median limb fat increase Median trunk fat increase grammi 48 weeks 96 weeks 48 weeks 96 weeks p= ns p= ns p=0.001 p= ns Mono 67 patients Triple 74 patients Valantin M et al. HIV Med. 2012; Mar 14
64 M03-613: Changes in Bone Mineral Density from baseline to week 96 DEXA scans: baseline, every 24 weeks through Wk 96 (n = 106) Brown TT, et al. JADIS. 2009;51:
65 Patients with viral load <50 copies/ml at Week 48 (%) DUET: Virological response at Week 48 (TLOVR) with fully active ETR and fully active DRV p=0.0011* 74% ETR + BR (n=227) Placebo + BR (n=236) p=0.0177* 83% p=0.0283* 80% 71% 64% 53% p=n/a 100% 86% /108 57/107 62/75 55/78 33/41 28/44 3/3 6/7 Number of active NRTIs in the BR (PSS) Total number of active agents used (including ETR + DRV) Fully active ETR = patients with ETR FC 3; DRV = patients with DRV FC 10; ETR and DRV were not included in the PSS calculation; Analysis excludes patients who discontinued for reasons other than VF; *Logistic regression; According to Antivirogram N.Clumeck, ET AL.
EACS 2013. Dominique Braun Universitätsspital Zürich
EACS 2013 Switch data Rilpivirine: Swing-trial Elvitegravir: Flamingo-trial Simplification Dual-Therapy: LPV/r + 3TC in the Gardel-trial Mono-Therapy: Darunavir/r mono in clinical setting Boceprevir/Telaprevir
Die Toronto Konferenz. K. Arasteh Auguste-Viktoria-Klinikum
Die Toronto Konferenz K. Arasteh Auguste-Viktoria-Klinikum Subjektive Schwerpunkte Medizinische Prävention Monotherapie CD4 guided treatment interuption (CD4-TI) HIV Prävention (Gita Ramjee) Rationale
HIV Drug resistanceimplications
HIV Drug resistanceimplications for therapy Deenan Pillay Africa Centre for Health and Population Studies, UKZN University College London Potential implications of HAART without virological monitoring:
Low level viremia and HIV-1 drug resistance in patients with virological rebound after suppression with a first line antiretroviral regimen
Low level viremia and HIV-1 drug resistance in patients with virological rebound after suppression with a first line antiretroviral regimen Manuela Colafigli Catholic University of S. Heart Rome, Italy
Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load
Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation M Dinaker INTRODUCTION The wide availability of effective, safe and mostly well tolerated combined anti-retroviral therapy (CART)
Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA
Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading cause of death amongst HIV-positive
Switch to Dolutegravir plus Rilpivirine dual therapy in cart-experienced Subjects: an Italian cohort
Switch to Dolutegravir plus Rilpivirine dual therapy in cart-experienced Subjects: an Italian cohort Gaetana Sterrantino Azienda Ospedaliero-Universitaria Careggi Infectious diseases, Florence, Italy Background
Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH
TREATMENT FAILURE AND PATTERNS OF GENOTYPIC DRUG RESISTANCE MUTATIONS AMONG HAART EXPERIENCED HIV-1 PATIENTS AT KCMC Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH
HIV Guidelines. New Strategies.
HIV Guidelines. New Strategies. Santiago Moreno Hospital Universitario Ramón y Cajal Madrid HIV Guidelines. New Strategies. Outline HIV Guidelines What is new? New strategies Treatment as Prevention HIV
Poster # 42 Resistance in PBMCs Can Predict Virological Rebound after Therapy Switch in cart- Treated Patients with Undetectable HIV-RNA
Poster # 42 Resistance in PBMCs Can Predict Virological Rebound after Therapy Switch in cart- Treated Patients with Undetectable HIV-RNA D Armenia 1, M Zaccarelli 2, V Borghi 3, W Gennari 3, A Giannetti
La sospensione dell ARV è sempre una cattiva idea?
15/05/2014 La sospensione dell ARV è sempre una cattiva idea? Adriano Lazzarin IRCCS Ospedale San Raffaele, Università Vita e Salute, Milano 6 Infectivology Today I due principi che guideranno il management
Antiretroviral therapy for HIV infection in infants and children: Towards universal access
Antiretroviral therapy for HIV infection in infants and children: Towards universal access Executive summary of recommendations Preliminary version for program planning 2010 Executive summary Tremendous
Clinical rationale for viral load testing
Clinical rationale for viral load testing Francois Venter Wits Reproductive Health & HIV Institute Caveats I m a believer in VLs My talk looks at resource poor environments Why do we need a rationale???
Generic antiretrovirals in Europe: a blessing or a curse?
Generic antiretrovirals in Europe: a blessing or a curse? Ricardo Jorge Camacho 1 Molecular Biology Laboratory, Centro Hospitalar de Lisboa Ocidental 2 Instituto de Higiene e Medicina Tropical, Universidade
ARV treatment Update 2012. Avondseminarie 18 december 2012 Eric Florence ITG, Antwerpen
ARV treatment Update 2012 Avondseminarie 18 december 2012 Eric Florence ITG, Antwerpen Three big conferences in 2012 http://retroconference.org/2012/ http://www.aids2012.org/ http://www.hiv11.com/ Current
HIV/AIDS: Controversies 2008-10
HIV/AIDS: Controversies 2008-10 1. Prevention 2. Treatment Josep M Gatell Hospital Clinic. Barcelona. gatell0@attglobal.net AIDS: year 2008-10 AIDS is a STD and a world wide epidemy (sub-saharan Africa,
Paediatric HIV treatment update
Paediatric HIV treatment update James Nuttall Red Cross War Memorial Children s Hospital & University of Cape Town ART Resistance & New Treatment Options 6 th FIDSSA Conference, 5-7 November 2015 ART Eligibility
Treating HIV in children with tuberculosis
International AIDS Society - Industry Liaison Forum Meeting 5 March 2012 Treating HIV in children with tuberculosis Helen McIlleron, Division of Clinical Pharmacology University of Cape Town Challenges
Safety of Nucleos(t)ide Analogues during Long-Term Treatment of Chronic Hepatitis B
Safety of Nucleos(t)ide Analogues during Long-Term Treatment of Chronic Hepatitis B Anna S. F. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology University
Treatment 2.0 as a catalyst for Tasp through Drug / Treatment Optimization
Treatment 2.0 as a catalyst for Tasp through Drug / Treatment Optimization STEFANO VELLA MD ISTITUTO SUPERIORE DI SANITÀ ROME - ITALY DDF 6 WAFAA EL SADR, CROI 2012 The problem is in how to efficiently
Management of HIV/HCV Co-infected Patients
Management of HIV/HCV Co-infected Patients David Wyles, MD Associate Professor of Medicine Division of Infectious Diseases University of California, San Diego San Diego, California Disclosures Grants/Research
London Therapeutic Tender Implementation: Guidance for Clinical Use. 4 th June 2014 FINAL
London Therapeutic Tender Implementation: Guidance for Clinical Use 4 th June 2014 FINAL Contents 3. General principles 4. Financial impact of therapeutic tendering for branded ARVs 5. London ARV algorithm:
Protease Inhibitor Resistance at 2nd-line HIV Treatment Failure in Sub-Saharan Africa
Protease Inhibitor Resistance at 2nd-line HIV Treatment Failure in Sub-Saharan Africa T. Sonia Boender; Raph L. Hamers; Pascale Ondoa; Maureen Wellington; Cleophas Chimbetete; Margaret Siwale; Eman E F
Paediatric HIV Drug Resistance in African Settings
Paediatric HIV Drug Resistance in African Settings Dr Cissy Kityo Mutuluuza INTEREST Meeting May 5-9, 2014 Lusaka, Zambia Background: ART for children in sub- Saharan Africa 2.3 million children with HIV
HBV screening and management in HIV-infected children and adolescents
HBV screening and management in HIV-infected children and adolescents Linda Aurpibul M.D. Research Institute for Health Sciences, Chiang Mai University 8% HIV and Hepatitis B Co-infection Among Perinatally
Antiretroviral Drugs in the Treatment and Prevention of HIV Infection
Antiretroviral Drugs in the Treatment and Prevention of HIV Infection Noga Shalev, MD Uses of Antiretroviral Agents Treatment of chronic HIV infection Prevention of mother-to-child transmission [PMTCT]
Hepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total
Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006)
r 2006 British HIV Association HIV Medicine (2006), 7, 487 503 British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006) B Gazzard on behalf
HIV/Hepatitis C co-infection. Update on treatment Eoin Feeney
HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients
Second Silibinin Workshop, Cologne, 23 rd May 2014 Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients Dominique L Braun, MD Division of
Coinfezione HIV-HCV. Raffaele Bruno, MD. Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Coinfezione HIV-HCV Raffaele Bruno, MD This program is supported by educational grants from Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Co-infected health-care workers
Co-infected health-care workers Y.Yazdanpanah Service Universitaire des Maladies Infectieuses et du Voyageur C.H. Tourcoing, Faculté de Médecine de Lille CNRS U362, Lille, France Co-infected health-care
Need & the state of the art
Need & the state of the art Long-term treatment What problems in the antiretroviral therapy today? Compliance Adherence Toxicity Failure Resistance Andreoni November 2013 Antiretroviral agents in clinical
Post AASLD Update in HCV Torino, 10 Gennaio 2013. Fattori che possono influenzare il trattamento: RVR e Lead in
Post AASLD Update in HCV Torino, 10 Gennaio 2013 Fattori che possono influenzare il trattamento: RVR e Lead in Alessia Ciancio Università di Torino Città della Salute e delle Scienze Will predictors usefull
Understanding Pharmacokinetic Variability and Managing Drug Interactions
Understanding Pharmacokinetic Variability and Managing Drug Interactions Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious Diseases
HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment Guidance for Industry
Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
HEPATITIS COINFECTIONS
HEPATITIS COINFECTIONS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures (Activity w/i 12 months)
Antiretroviral Therapy for HIV Infection: When to Initiate Therapy, Which Regimen to Use, and How to Monitor Patients on Therapy
Perspective Antiretroviral Therapy for HIV Infection: When to Initiate Therapy, Which Regimen to Use, and How to Monitor Patients on Therapy Antiretroviral therapy is recommended for all patients with
Preferred Regimens as recommended by DHHS guidelines (listed by class) strength of evidence = A1
Recommendations for Use of Antiretroviral Regimens in HIV-infected Treatment-naïve Veterans March 2013 VHA Pharmacy Benefits Management Services, the Medical Advisory Panel, VISN Pharmacist Executives,
Optimising therapy in chronic hepatitis B: Switch or add treatment
Optimising therapy in chronic hepatitis B: Switch or add treatment Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University,Thailand NA + NA Percent with resistance
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova HBV ed HCV Due virus Diversi ma con molte Cose in Comune
Cytoreductive Therapy for Autologous Cell Therapy in HIV
Cytoreductive Therapy for Autologous Cell Therapy in HIV Ronald Mitsuyasu, MD Professor of Medicine UCLA Center for Clinical AIDS Research and Education (CARE Center) HSC Transfer from CCR5-delta 32 Donor
DOI: 10.1111/hiv.12119 2014 British HIV Association HIV Medicine (2014), 15 (Suppl. 1), 1 85
DOI: 10.1111/hiv.12119 British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.)
Hepatitis C Vaccines: Are we making progress?
Hepatitis C Vaccines: Are we making progress? Second International Hepatitis Cure and Eradication Meeting. Vancouver November, 2015 Objectives: Review the need for a preventive vaccine in 2015. Identify
Reference: NHS England B06/P/a
Clinical Commissioning Policy: Dolutegravir for treatment of HIV- 1 in adults and adolescents Reference: NHS England B06/P/a 1 NHS England Clinical Commissioning Policy: Dolutegravir for treatment of HIV-1
Chapter 3 South African guidelines and introduction to clinical cases
Chapter 3 South African guidelines and introduction to clinical cases 3.1. South African national antiretroviral guidelines When this book was published in 2012 the current national antiretroviral treatment
Long-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B
Long-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B Patrick Marcellin Viral Hepatitis Research Center Hôpital Beaujon, University of Paris France OBJECTIVES OF THERAPY IN CHRONIC
HIV and Hepatitis B CoInfection
HIV and Hepatitis B CoInfection Douglas G. Fish, MD June 3, 2014 44 yo male with AIDS who had fallen out of care and returned in October 2013 Last seen in November 2012 CD4 at that time 340 cells/cmm HIV
How To Understand And Understand The Health Effects Of Hiv In Spain
BHIVA AUTUMN CONFERENCE 2010 Including CHIVA Parallel Sessions Dr José Tomás Ramos Amador University of Madrid, Spain 7-8 October 2010, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the
Meeting Report 15 th PK Workshop, Washington, 2014 Produced by www.hiv-druginteractions.org
Page 1 of 7 HIV Interaction Studies presented at the 15 th International Workshop on Clinical Pharmacology of HIV and HCV Therapy, Washington, April 2014. This report summarises interaction studies relating
Newton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP
Newton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP I do not have any relevant financial relationships with any commercial interests. At the end of
Hepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS
Hepatitis B and C Co-infection Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Objectives Review natural history of hepatitis coinfection Brief overview of treatment indications for
Aktuell HIV-forskning 2014-05-06
Aktuell HIV-forskning 2014-05-06 Alexey Kashpersky Aktuell HIV-forskning Bot Smittsamhet Nya läkemedel HIV och åldrande Etc HPTN 052 Prevention Conclusion Early ART that suppresses viral replication led
STUDY PROGRESS AND SAFETY MONITORING PLAN TEMPLATE
STUDY PROGRESS AND SAFETY MONITORING PLAN TEMPLATE (Intended primarily for use in monitoring of Phase III/IV trials) Final December 20, 2006 20 DEC 06; Version 2.0 1 of 15 No.: DWD-POL-SR-01.00A2 TABLE
Didactic Series. Updated Post-Exposure Prophylaxis (PEP) Guidelines. Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014
Didactic Series Updated Post-Exposure Prophylaxis (PEP) Guidelines Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014 ACCREDITATION STATEMENT: University of California, San Diego School of
Prevalenza HIV/HCV in Italia
Prevalence of HIV/HCV co-infection by region, 2013 WHO global systematic review of prevalence of HIV/HCV Ab co-infection based on prevalence studies in HIV+ persons stratified by risk group (where available)
Slide 1 HIV/ HCV Coinfected people: what are the specific concerns they face?
Slide 1 HIV/ HCV Coinfected people: what are the specific concerns they face? Marion Peters MD University of California San Francisco 2011 Slide 2 Special issues Effect of HIV on HCV Effects of HCV on
Management of HCV/HIV co-infection in the era of DAA-based therapy
Management of HCV/HIV co-infection in the era of DAA-based therapy Jürgen K. Rockstroh Department of Internal Medicine I University Hospital Bonn Germany Conflict of interest I have received honoraria
Robert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012
Treatment of Hepatitis C:Present and Future Robert G. Knodell, M.D. Scientific Meeting Maryland Chapter, American College of Physicians Fb February 3, 2012 Presentation Objectives Appreciate the Public
Monitoring of Treatment of viral hepatitis C
Monitoring of Treatment of viral hepatitis C J.Boubaker Department of Gastroenterology La Rabta hospital Tunis-Tunisia Monitoring of Hepatitis C Treatment Aims of Monitoring : Evaluate Efficacy. Detect
Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
Acute HCV was defined as (3 out of 4 within the preceding 4 months):
Christoph Boesecke, Patrick Ingiliz, Hans-Jürgen Stellbrink, Mark Nelson, Sanjay Bhagani, Marguerite Guiguet, Marc-Antoine Valantin, Thomas Reiberger, Martin Vogel, Jürgen K. Rockstroh, and the NEAT study
Liver Disease and Therapy of Hepatitis B Virus Infections
Liver Disease and Therapy of Hepatitis B Virus Infections University of Adelaide Catherine Scougall Arend Grosse Huey-Chi Low Allison Jilbert Fox Chase Cancer Center Chunxiao Xu Carol Aldrich Sam Litwin
FARMACI, INNOVAZIONE e INFEZIONE DA HIV / AIDS
FARMACI, INNOVAZIONE e INFEZIONE DA HIV / AIDS Stefano Vella Dipartimento del Farmaco Istituto Superiore di Sanità - Roma Stages of HIV-1 Life Cycle Targeted by Anti-HIV Drugs In: Gulick RM, Topics HIV
Clinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
HIV/HCV Co-Infection
HIV/HCV Co-Infection 2015 Kentucky Conference on Viral Hepatitis Matt Cave, M.D. Associate Professor Department of Medicine Division of Gastroenterology, Hepatology, & Nutrition Department of Pharmacology
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2013
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2013 VERSION 14 March 2013 Contents Acronym glossary... 2 1. Goals of the programme... 3 2. Objectives... 3 3. Specific Objectives... 3 4. Adults and
Journal of Infectious Diseases Advance Access published January 26, 2015
Journal of Infectious Diseases Advance Access published January 26, 2015 1 Effect of immune status on serial QuantiFERON-TB Gold In-Tube LTBI screening in persons with HIV in a low TB incidence country
Oral Presentation at EACS2007 # PS3/1. OK04 trial design. LPV/r SGC 400/100 mg BID ( OK ) (n=100)
Lopinavir/ritonavir monotherapy versus lopinavir/ritonavir and two nucleosides for maintenance therapy of HIV. Ninety-six week results of a randomized, controlled, open-label clinical trial ( Study). Arribas
The question and answer session is not available after the live webinar.
1 Read verbatim. 2 The Infectious Diseases Society of America (IDSA) Hepatitis C Knowledge Network offers monthly, 1 hour webinars to educate IDSA members on current recommended practices and treatments
Incidencia y Características Clínicas del Síndrome Inflamatorio de Reconstitución Inmune (IRIS) en el Contexto de la Coinfección VIH-TB
Incidencia y Características Clínicas del Síndrome Inflamatorio de Reconstitución Inmune (IRIS) en el Contexto de la Coinfección VIH-TB Dr. Christian Manzardo Hospital Clínic/IDIBAPS- Universidad de Barcelona
Regulatory Approach in Germany and in the EU to Fixed Dose Combination Medicinal Products Using HIV/AIDS Treatment as an Example
Regulatory Approach in Germany and in the EU to Fixed Dose Combination Medicinal Products Using HIV/AIDS Treatment as an Example Prof. Dr. rer. nat. habil. Harald G. Schweim President Federal Institute
Routine HIV Monitoring
Routine HIV Monitoring Guideline of the HIV/AIDS Division at San Francisco General Hospital Statement of Guideline: Patients will be routinely evaluated and monitored for HIV parameters, antiretroviral
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
New treatment options for HCV: implications for the Optimal Use of HCV Assays
New treatment options for HCV: implications for the Optimal Use of HCV Assays Hans Orlent Dept. of Gastroenterology & Hepatology AZ Sint Jan Brugge-Oostende, Brugge This program is supported by educational
HIV. Head - Paediatric HIV Treatment Programmes. Right to Care. Dr Leon Levin
HIV Dr Leon Levin Head - Paediatric HIV Treatment Programmes Right to Care Disclaimer This talk represents my personal experience in managing teenagers with HIV over the last 14 years. It does not purport
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS
Prospects for Vaccines against Hepatitis C Viruses T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS HCV Vaccine Prevention strategies Protective immunity Barriers and solutions Vaccine candidates
Chapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections
Chapter 36 Media Directory Drugs for Viral Infections Slide 23 Slide 27 Slide 29 Zidovudine Animation Saquinavir Mesylate Animation Acyclovir Animation Upper Saddle River, New Jersey 07458 All rights reserved.
Consolidated guidelines on the use of antiretroviral drugs for treating
TB conference, 10-13 June 2014, Durban, South Africa Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Dr Augustin Ntilivamunda Objectives of 2013 WHO
NEW INSIGHTS INTO MANAGING HIV-1
Learning Objectives Integrate recent clinical trial data into updated HIV management guidelines to provide the most individualized treatment for HIV-1-infected patients Develop a patient-centered approach
HIV/HCV Co-infection. HIV/HCV Co-infection. Epidemiology. Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London. Extrahepatic manifestations
HIV/HCV Co-infection Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London HIV/HCV Co-infection Epidemiology Impact of HIV on HCV Epidemiology Impact of HCV on HIV Management issues Future Extrahepatic
AAB 2013 Annual Meeting & Educational Conference
American Association of Bioanalysts AAB 2013 Annual Meeting & Educational Conference Occult Hepatitis and HIV Prophylaxis Thursday, May 16, 2013, 9:45 a.m. John H. Hughes, Ph.D. Dept Molecular Virology,
Cirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052)
Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C PIs: atazanavir PIs: other Simeprevir with ritonavir- or cobicistat boosted PIs (significant simeprevir AUC).
UPDATE IN HIV POST-EXPOSURE PROPHYLAXIS. Weerawat Manosuthi
UPDATE IN HIV POST-EXPOSURE PROPHYLAXIS Weerawat Manosuthi Outline Case scenario of postexposure prophylaxis Risks of and how to manage postexposure prophylaxis Current PEP guideline US PHS 2013 New York
Cure versus control: Which is the best strategy?
Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control
Clinical Commissioning Policy: Stribild for the treatment of HIV-1 infection in adults
Clinical Commissioning Policy: Stribild for the treatment of HIV-1 infection in adults Reference: NHS England B06/P/x 1 Clinical Commissioning Policy: Stribild for the treatment of HIV-1 infection in adults
Up to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data).
HIV Background, new developments, key strategies Drug Class Insight INTRODUCTION Human Immunodeficiency Virus (HIV) is the virus that can lead to Acquired Immunodeficiency Syndrome, or AIDS. No safe and
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C
Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Debra Birnkrant, MD Director, DAVP DILI Conference March 20, 2013 1 HCV in the United States 3 to 4 million people have chronic HCV
Molecular Diagnosis of Hepatitis B and Hepatitis D infections
Molecular Diagnosis of Hepatitis B and Hepatitis D infections Acute infection Detection of HBsAg in serum is a fundamental diagnostic marker of HBV infection HBsAg shows a strong correlation with HBV replication
Current Opinion in Hepatitis C Treatment
White Nights of Hepatology 2011 Current Opinion in Hepatitis C Treatment George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.
Pharmacodynamics and Drug-Drug Interactions in HCV/HIV Co-Infected Persons on Treatment with DAAs
Pharmacodynamics and Drug-Drug Interactions in HCV/HIV Co-Infected Persons on Treatment with DAAs Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and